文章：

卵巢癌：克服化疗耐药性的策略

Ovarian cancer: strategies for overcoming resistance to chemotherapy

原文发布日期：2003-07-01

DOI: 10.1038/nrc1123

类型: Review Article

开放获取: 否

要点：

1. The standard care for ovarian cancer is a combination of surgery and chemotherapy.
2. Carboplatin and paclitaxel form the cornerstone of chemotherapy in ovarian cancer.
3. In patients with tumour-cell dissemination beyond the ovaries, most relapse and ultimately die due to the development of drug resistance.
4. Drug resistance can arise due to pharmacokinetic, tumour micro-environmental and cancer-cell-specific abnormalities.
5. A number of resistance mechanisms have been defined in vitro. However, the importance of these in patients remains unclear.
6. Novel experimental approaches for analysis of clinical samples, such as comparative genomic hybridization, expression profiling and tissue microarrays, are likely to improve our understanding of drug resistance in patients.
7. Pharmacokinetic approaches to overcoming drug resistance, such as intraperitoneal chemotherapy and high-dose chemotherapy, are under evaluation.
8. A number of novel cytotoxic agents and drugs that target cell survival, drug resistance and apoptotic pathways are now entering clinical trials, and are aimed at overcoming drug resistance.

要点翻译：

1. 卵巢癌的标准治疗方案是手术与化疗相结合。
2. 卡铂和紫杉醇是卵巢癌化疗的基石疗法。
3. 对于肿瘤细胞扩散至卵巢以外的患者，多数会因产生耐药性而复发并最终死亡。
4. 耐药性的产生可归因于药代动力学、肿瘤微环境及癌细胞特异性异常等多种因素。
5. 目前已在体外实验中明确了多种耐药机制，但这些机制在患者体内的作用尚不清楚。
6. 采用新型实验方法分析临床样本（如比较基因组杂交、表达谱分析及组织微阵列技术）有望增进我们对患者耐药机制的理解。
7. 针对克服耐药性的药代动力学策略（如腹腔内化疗和大剂量化疗）正在评估中。
8. 多种靶向细胞存活、耐药性及凋亡通路的新型细胞毒药物目前正进入临床试验阶段，旨在克服耐药性问题。

英文摘要：

Ovarian cancer is responsible for 4% of deaths from cancer in women. Treatment comprises a combination of surgery and chemotherapy, but patients typically experience disease relapse within 2 years of the initial treatment. Further treatment can extend survival, although relapse eventually occurs again. A better understanding of the mechanisms that underlie this drug resistance should allow treatment to be optimized, so that substantial improvements in the outlook for women with this disease can be achieved.

摘要翻译： 

卵巢癌占女性癌症死亡的4%。治疗包括手术和化疗的结合，但患者通常在初始治疗后的2年内经历疾病复发。进一步的治疗可以延长生存期，尽管复发最终仍会发生。更好地理解这种耐药机制将有助于优化治疗，从而显著改善患有该疾病的女性的预后。

原文链接：

Ovarian cancer: strategies for overcoming resistance to chemotherapy